NVCR News and Press, NovoCure Limited From 01/18/24

NovoCure Limited (NASDAQ: NVCR) is one of today's top gainers. The company's shares have moved 3.24% on the day to $13.05. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company...

2024-01-18 07:24:27 ET More on NovoCure, Zai Lab, etc. Zai Lab: Strong Growth Amidst Strategic Shifts (Rating Upgrade) NovoCure: Significant Upside Even Without A Breakthrough Zai Lab Limited (ZLAB) Q3 2023 Earnings Call Transcript Novocure reports better-tha...

Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after plati...

2024-01-12 16:40:04 ET Gainers: Outset Medical ( OM ) +11% . Kandi Technologies Group ( KNDI ) +7% . Dyne Therapeutics ( DYN ) +5% . Revance Therapeutics ( RVNC ) +4% . NovoCure Limited ( NVCR ) +3% . Losers: Gritstone&#x...

2024-01-10 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Final data from the TRIDENT trial anticipated in 2026 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio ® (formerly known as Optune ® ...

2024-01-08 07:45:24 ET More on NovoCure NovoCure: Significant Upside Even Without A Breakthrough NovoCure gains on participation at J.P. Morgan Healthcare Conf. Novocure to eliminate 13% of workforce in restructuring effort For further details see: Novocu...

Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D., Ph.D. appointed as Novocure Chief Medical Officer, effectiv...

2024-01-04 16:16:45 ET More on NovoCure NovoCure: Significant Upside Even Without A Breakthrough Novocure to eliminate 13% of workforce in restructuring effort For further details see: Novocure appoints Nicolas Leupin as its chief medical officer

Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medic...